Lamotrigine Tablet, For Suspension
Product Images NDC 62332-096

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 62332-096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lamotrigine 25mg Os

Lamotrigine Tablets for Oral Suspension USP, 25 mg strength, in tablet form intended for suspension, labeled for oral use. The label states a package count of 30 tablets and indicates prescription-only status. Manufactured by Alembic Pharmaceuticals Inc., with additional manufacturer information from Alembic Pharmaceuticals Limited, India. Contains storage instructions, cautions, and a barcode for identification.*

FDA Label Image

Lamotrigine 5mg Os

Lamotrigine Tablets for Oral Suspension, USP 5 mg label from Alembic Pharmaceuticals Inc. The label states the strength as 5 mg per tablet for suspension, with 30 tablets per container. It includes storage instructions, phenylketonurics warning, and manufacturer details from Alembic Pharmaceuticals Limited, Gujarat, India. The label also features the Alembic logo and barcode.*

FDA Label Image

Figure 1 (Lamotrigine Figure1)

A Kaplan-Meier failure probability curve comparing lamotrigine and placebo over a period of approximately 90 weeks. The vertical axis shows failure probability percentage, and the horizontal axis shows time in weeks. The graph includes censored data points and labels for both treatment groups.*

FDA Label Image

Figure 2 (Lamotrigine Figure2)

A Kaplan-Meier survival curve chart depicting failure probability (%) over weeks for lamotrigine compared to placebo. The chart shows two stepwise curves labeled 'Lamotrigine' and 'Placebo' with censored data points marked. Failure probability increases over time, with the placebo group showing higher failure rates than the lamotrigine group across approximately 80 weeks.*

FDA Label Image

Figure (Lamotrigine Figure3)

This image shows the tablet identification markings for lamotrigine oral suspension tablets. The 5 mg tablets are white to off-white and debossed with 'L217'. The 25 mg tablets are white to off-white and debossed with '218' on one side and 'L' on the other side.*

FDA Label Image

Structure (Lamotrigine Structure)

Chemical structure of lamotrigine, showing the molecular arrangement with chlorine atoms and nitrogen-containing rings consistent with its compound structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.